Why Does My Medical Device Project Keep Missing Milestones?

If you are watching your medical device project blow past milestone after milestone, you are not alone. Companies large and small routinely underestimate how long it takes to bring a device to market, and the consequences—burned cash, lost competitive advantage, and frustrated investors—pile up fast.

This guide walks through the real reasons medical device timelines slip, how each one compounds into bigger problems, and concrete steps you can take to recover and protect your schedule going forward.

The Scale of the Problem

Before diagnosing root causes, it helps to calibrate expectations. Many teams build plans that assume a 12-month sprint from prototype to clearance. The reality is starkly different. For most Class II medical devices cleared through the 510(k) pathway, the realistic planning range is 18 to 36 months from concept to commercial launch. For high-risk Class III devices requiring the PMA pathway, the journey can stretch to 7–10 years with costs exceeding $31 million on average.

With that context, let us look at the specific failure modes that cause milestones to slip.

Root Cause 1: Best-Case Planning

The most pervasive mistake is building a schedule that assumes everything goes right. Even if the plan represents average task durations, there is roughly a 50% chance of being late. Real-world deviations are rarely small adjustments; they tend to produce stepwise delays. A late component delivery might push a timeline back by one week, but an unexpected test failure could require an entirely new design integration cycle.

What this looks like in practice

• Gantt charts with zero float on critical-path activities
• No contingency time allocated for regulatory feedback loops
• Testing durations based solely on lab execution time, ignoring scheduling lead time, sample preparation, report generation, and rework

Root Cause 2: Poorly Defined or Shifting Requirements

Medical devices are designed to meet requirements that address well-understood user needs. Those requirements inform every design decision downstream. When requirements change mid-development, they can invalidate prior decisions and dramatically increase the effort required to get back on track.

The best practice is to define clear, comprehensive requirements from the start, covering not only core user needs but also regulatory requirements, data security, interoperability, and reimbursement considerations. Bring all stakeholders—engineering, clinical, regulatory, and marketing—into the requirements process early.

Root Cause 3: Verification and Validation Becomes a Black Hole

This is the phase where most medical device timelines break. Teams often plan testing as a short, linear step. In reality, FDA expectations and real-world lab constraints make testing iterative, interdependent, and delay-prone.

Why V&V eats schedules

• Test failures cascade: A biocompatibility or performance failure does not just require a retest. It can force a redesign that invalidates every downstream test already scheduled or completed.
• Sterilization validation sits on the critical path: It cannot begin until packaging, bioburden, and material selections are finalized. A failure here can invalidate multiple prior tests.
• Lead time blindness: A common planning error is equating test duration with lab execution time while ignoring the weeks needed to schedule the lab, prepare samples, generate reports, and handle any rework.

Teams that treat testing as a coordinated program rather than a checklist are far better equipped to manage these dependencies.

Root Cause 4: Regulatory Work Treated as an Afterthought

Many companies treat regulatory documentation as a separate task bolted on at the end rather than integrated into development. This is a recipe for delay. Bringing a medical device to market requires extensive documentation—design history files, device master records, risk management files, test reports, and clinical evidence. Gaps in risk management documentation under ISO 14971 are a particularly common cause of submission delays.

Making matters worse, around 60% of FDA submissions receive at least one major information request. Each additional information (AI) request typically extends the overall timeline by months, especially when new testing, revised analyses, or predicate changes are required. Multiple AI cycles compound delays and increase regulatory risk.

Root Cause 5: Insufficient Reviews and Late Problem Detection

The later design issues are caught, the more problematic and time-consuming they are to fix. Many problems would be discovered early with thorough, independent project reviews. Yet teams often skip formal design reviews or treat them as rubber-stamp exercises, only to discover fundamental issues during verification testing or, worse, during FDA review.

Root Cause 6: Supply Chain and Manufacturing Transfer Surprises

Sourcing raw materials and components from multiple suppliers introduces coordination risk. When sourcing from a dozen different suppliers, every material and component must arrive on time to start assembly. Consolidating suppliers where possible makes logistics more manageable.

The manufacturing transfer phase is frequently underestimated in medical device development timelines. Process validation, equipment qualification, supplier qualification, and quality management system audits all take time. Discovering a manufacturing process issue after clearance is a scenario worth heavy upfront investment to avoid.

How to Fix Your Medical Device Project Timeline

Now that the failure modes are clear, here are actionable steps to recover a slipping project or prevent delays on your next one.

Step 1: Re-Baseline with Realistic Durations

Throw away best-case timelines. Rebuild your schedule using probabilistic estimates that account for rework, lab lead times, and regulatory feedback loops. Add explicit contingency buffers on your critical path. Think about the end goal and factor timelines out from that, rather than planning only the next incremental step.

Step 2: Lock Requirements Early and Manage Changes Ruthlessly

Invest the time upfront to capture comprehensive requirements from all stakeholders. Once locked, treat any requirement change as a formal change order with a documented impact analysis on schedule, budget, and regulatory strategy. Avoid the temptation to accommodate scope creep without adjusting milestones.

Step 3: Map Testing Dependencies Before You Start

Create a testing dependency map that shows which tests feed into others, which share samples or equipment, and which sit on the critical path. Identify sterilization validation and biocompatibility testing as high-risk activities and schedule them with maximum lead time. Coordinate testing as a program, not a checklist of isolated tasks.

Step 4: Integrate Regulatory Compliance from Day One

Engaging a regulatory affairs expert at the outset can save enormous time and cost later. Make regulatory compliance a built-in design requirement, not an afterthought. Maintain your design history file, risk management file, and other documentation in real-time rather than reconstructing them before submission. Use pre-submission meetings with FDA to align on expectations before investing months in testing strategies that might miss the mark.

Step 5: Institute Rigorous Phase-Gate Reviews

Formal design reviews at each phase gate should include independent technical reviewers who are not emotionally invested in the project's momentum. Review against objective exit criteria, not subjective confidence. Pay special attention to risk management file completeness, requirements traceability, and testing readiness.

Step 6: Bring In Expert Resources Where You Have Gaps

If your team is overwhelmed by tight deadlines, missing critical knowledge, or stretched across too many priorities, the schedule will continue to slip. An experienced medical device consulting partner can provide program management, cross-functional engineering leadership, and regulatory expertise to close gaps without the overhead of permanent hires.

A65 Consulting specializes in exactly this scenario. Their engineering team covers the entire product lifecycle, from research and conceptualization through development, manufacturing transfer, and cost optimization. They work toward mutually agreed-upon project milestones and provide cross-functional leadership to keep management informed of project status through regular presentations and reports.

Step 7: Use Your QMS as a Strategic Tool, Not a Checkbox

Working out of a quality management system is a basic requirement for medical device manufacturers, but viewing it as a checkbox activity diminishes the massive value it can provide. A properly leveraged QMS enforces the discipline of design controls, ensures documentation is captured as work happens, and provides early warning when processes deviate from plan.

Key Takeaways

• Medical device timelines fail not because teams are incompetent, but because early plans ignore how design controls, testing dependencies, and FDA interaction actually work.
• Verification and validation is the phase most likely to blow up your schedule—plan it as a coordinated program with explicit dependency mapping.
• Regulatory documentation must be a continuous thread from concept through post-launch, not a bolt-on at the end.
• Roughly 60% of FDA submissions trigger at least one additional information request, adding months per cycle.
• Independent design reviews catch problems early when they are cheapest to fix.
• Expert consulting resources can recover stalled projects by providing leadership, domain expertise, and structured project management.

Frequently Asked Questions

Why do medical device projects consistently miss milestones?

The primary drivers are overly optimistic planning, requirement changes mid-development, underestimated testing lead times, and insufficient design reviews. Each of these individually causes delays, but they frequently occur together and compound each other.

How long should I really plan for a Class II 510(k) medical device?

Plan for 18 to 36 months from concept to commercial launch. This accounts for design complexity, testing interdependencies, and the reality that FDA review is only one part of the timeline—delays more commonly come from underestimating development effort and testing lead times.

What is the single biggest timeline risk in medical device development?

Verification and validation testing. Teams plan it as a short step, but it is iterative, interdependent, and delay-prone. A single test failure can cascade into redesign that invalidates downstream testing, and sterilization validation failures are particularly disruptive because they can undo multiple prior tests.

Can a medical device consulting firm help recover a stalled project?

Absolutely. A firm like A65 Consulting can provide interim engineering leadership, structured project management, and deep domain expertise to re-baseline schedules, close knowledge gaps, and restore momentum. Their team covers the full product lifecycle and works toward mutually agreed milestones.

How do FDA additional information requests affect my timeline?

About 60% of FDA submissions receive at least one major information request. Each AI request can extend the timeline by months, particularly when new testing or revised analyses are needed. When FDA issues multiple AI requests, the delays compound significantly.

Should I use the minimum viable product approach for medical devices?

The MVP concept can work in medical devices, but it requires careful alignment with the intended use and indications for use. The goal is to cover the minimum requirements for safety and efficacy to get a safe device to patients faster, while roadmapping non-critical features for future iterations.